Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech
Global pharmaceutical companies are aggressively searching for new medicines in ChinaTechnology, Artificial intelligence
Consulta l'articolo completo a questo indirizzo
https://www.ft.com/content/4efaf8cd-d415-46bb-8fb9-367e4eb3a781?segmentId=776b81d7-dd92-c731-e669-99cdd37d3a96#myft:my-news:rss



